Pittsburgh, PANCT06016179Now EnrollingIRB Ready

Malignant Pleural Effusion Clinical Trial in Pittsburgh, PA

Access cutting-edge malignant pleural effusion treatment through this phase 1 clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.

Sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Quick Self-Assessment

See if you qualify for this Pittsburgh location

Preparing your pre-screening questions…

Expert Care in Pittsburgh

Access malignant pleural effusion specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related malignant pleural effusion treatment provided free

Apply for This Pittsburgh Location

Check if you qualify for this malignant pleural effusion clinical trial in Pittsburgh, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Pittsburgh

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Pittsburgh site if eligible
  4. 4Begin participation

About This Malignant Pleural Effusion Study in Pittsburgh

The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE). Patients will have a total of 4 doses, one dose administered each week. Each dose will be greater than the previous one.

Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Who Can Participate

Inclusion Criteria

Males or females ages 18-89 years
Female patients must have a negative pregnancy test and agree to use contraception. Female patients receiving tocilizumab should maintain adequate contraceptive measures during and for a minimum of 90 days after the last dose of tocilizumab. Male patients receiving tocilizumab should maintain adequate contraceptive measures during and for a minimum of 60 days after the last dose of tocilizumab.
Biopsy-proven diagnosis of malignancy with cytologic or radiographic evidence of malignant pleural effusion or ascites
Scheduled to undergo standard-of-care pleural or peritoneal drainage catheter placement
Able to read and understand consent in English and provide informed consent

Exclusion Criteria

Pediatric patients
Laboratory abnormalities that indicate clinically significant inflammatory process AST/SGOT \> 2 times the upper limit of normal ALT/SGPT \> 2 times the upper limit of normal Total bilirubin \> 2 times the upper limit of normal Creatinine \> 2.5 mg/dL Hemoglobin \< 7 mg/dL White blood cell count \< 3,000/ mm3 Platelet count \< 70,000/mm3 Absolute neutrophil cell count \< 2,000 per mm3
Subjects who are unable to comply with study procedures including travel for weekly outpatient clinic visits
Pregnant and lactating women
Active immunotherapy within 30 days; concurrent chemotherapy or targeted therapy is permitted but for patients with a history of prior immunotherapy, the most recent dose should be \>30 days prior to the first treatment visit
Investigational drug use within 30 days prior to first treatment dose
History of systemic autoimmune disease (CRS, GCA, PJIA, RA, and SJIA)
Patient with known hypersensitivity to tocilizumab (IL-6)
Active infection
Medical contraindication or history of adverse reaction to acetaminophen or diphenhydramine

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Pittsburgh?

Yes, this clinical trial (NCT06016179) has an active research site in Pittsburgh, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Malignant Pleural Effusion Treatment Options in Pittsburgh, PA

If you're searching for malignant pleural effusion treatment options in Pittsburgh, PA, this clinical trial (NCT06016179) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Pittsburgh research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced malignant pleural effusion specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all malignant pleural effusion clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Pittsburgh, PA

See all rheumatoid arthritis clinical trials recruiting in Pittsburgh — not just this study.

Browse Rheumatoid Arthritis Trials in Pittsburgh →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsAll Conditions →

Ready to Join in Pittsburgh?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Pittsburgh, PA